Amarin fends off supplement makers in fight over Vascepa CV data by Kyle Blankenship Wednesday, May 8, 2019 Aiming to protect Vascepa's CV advantage—and its fast-growing prescription count—Amarin's fighting supplement makers in court.
Amarin's Vascepa offers extended CV benefits by Angus Liu Monday, March 18, 2019 The fish oil-derived drug showed significant reduction not just in first cardiovascular events, but in recurrent incidence as well.
Believe it: Amarin's Vascepa delivers in big heart-risk study by Tracy Staton Monday, September 24, 2018 Call it a promise kept. Amarin has staunchly promised that Vascepa could prove it cuts heart risks, despite detractors' disbelief—and now it has.
JPM execs speak on 2018: Pricing moves, yes. M&A frenzy, no by Tracy Staton Monday, January 15, 2018 The J.P. Morgan Healthcare Conference was a great place to suss out the general biopharma mood as 2018 begins.
